Intravesical Pharmacotherapy for Non-Muscle-Invasive Bladder Cancer: A Critical Analysis of Currently Available Drugs, Treatment Schedules, and Long-Term Results

European Urology

Volumn 53, Issue 1, 2008, Pages 45-52

  Witjes, J Alfred ^a   Hendricksen, Kees ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Non muscle invasive; Therapy; Urothelial cell carcinoma

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ALPHA INTERFERON; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BCG VACCINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; ISONIAZID; MITOMYCIN C;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DRUG EFFICACY; DRUG INSTILLATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSURIA; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INSTILLATION, DRUG; NEOPLASM INVASIVENESS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 36448950859     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.08.015     Document Type: Review

References (50)

1. Avritscher E.B., Cooksley C.D., Grossman H.B., et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68 (2006) 549-553
2. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
3. Tolley D.A., Parmar M.K., Grigor K.M., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996) 1233-1238
4. Oosterlinck W., Kurth K.H., Schroder F., Bultinck J., Hammond B., and Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749-752
5. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153 (1995) 934-941
6. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
7. Campodonico F., Mattioli F., Manfredi V., et al. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. Anticancer Res 27 (2007) 1179-1183
8. Witjes J.A., van der Heijden A.G., Vriesema J.L., Peters G.J., Laan A., and Schalken J.A. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 45 (2004) 182-186
9. Beretta G. Bladder cancer. Mitomycin C (2001) p. 170-81
10. Onrust S.V., Wiseman L.R., and Goa K.L. Epirubicin: a review of its intravesical use in superficial bladder cancer. Drugs Aging 15 (1999) 307-333
11. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156 (1996) 1934-1940
12. Hendricksen K., Kiemeney L.A., Caris C.T.M., Janzing M.H.D., Witjes W.P.J., and Witjes J.A. Three schedules of adjuvant intravesical epirubicin in patients with non-muscle invasive bladder cancer: a comparative study. Eur Urol Suppl 6 (2007) 60 (abstract)
13. Au J.L., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (2001) 597-604
14. Laufer M., Ramalingam S., Schoenberg M.P., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 21 (2003) 697-703
15. Gontero P., Casetta G., Maso G., et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46 (2004) 339-343
16. Serretta V., Galuffo A., Pavone C., Allegro R., and Pavone-Macaluso M. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology 65 (2005) 65-69
17. Campodonico F., Canepa G., Capponi G., Bozzo L., and Maffezzini M. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res 25 (2005) 2381-2384
18. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24 (2006) 2729-2734
19. Bartoletti R., Cai T., Gacci M., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 66 (2005) 726-731
20. Walton M.I., Smith P.J., and Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 3 (1991) 199-206
21. Li D., Gan Y., Wientjes M.G., Badalament R.A., and Au J.L. Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors. J Urol 166 (2001) 2500-2505
22. van der Heijden A.G., Verhaegh G., Jansen C.F., Schalken J.A., and Witjes J.A. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 173 (2005) 1375-1380
23. van der Heijden A.G., Moonen P.M., Cornel E.B., et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176 (2006) 1349-1353
24. McKiernan J.M., Masson P., Murphy A.M., et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24 (2006) 3075-3080
25. Krege S., Giani G., Meyer R., Otto T., and Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. Participating clinics. J Urol 156 (1996) 962-966
26. Witjes J.A., vd Meijden A.P., Witjes W.P., Doesburg W., Schaafsma H.E., and Debruyne F.M. A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur J Cancer 29A (1993) 1672-1676
27. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
28. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
29. Gardmark T., Jahnson S., Wahlquist R., Wijkstrom H., and Malmstrom P.U. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int 99 (2007) 817-820
30. Friedrich M.G., Pichlmeier U., Schwaibold H., Conrad S., and Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52 (2007) 1123-1130
31. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
32. van der Meijden A.P., Sylvester R.J., Oosterlinck W., Hoeltl W., and Bono A.V. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 44 (2003) 429-434
33. van der Meijden A.P., Brausi M., Zambon V., Kirkels W., de B.C., and Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 166 (2001) 476-481
34. Colombel M., Saint F., Chopin D., Malavaud B., Nicolas L., and Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176 (2006) 935-939
35. Ojea A., Nogueira J.L., Solsona E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
36. Uchida A., Yonou H., Hayashi E., et al. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis. Urology 69 (2007) 275-279
37. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49 (2006) 790-797
38. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
39. Kiemeney L.A., Witjes J.A., Verbeek A.L., Heijbroek R.P., and Debruyne F.M. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 67 (1993) 806-812
40. Schrier B.P., Hollander M.P., van Rhijn B.W., Kiemeney L.A., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292-296
41. Joudi F.N., Smith B.J., and O'donnell M.A. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348
42. Colombo R., Da Pozzo L.F., Lev A., Freschi M., Gallus G., and Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 155 (1996) 1227-1232
43. Colombo R., Da Pozzo L.F., Salonia A., et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21 (2003) 4270-4276
44. van der Heijden A.G., Kiemeney L.A., Gofrit O.N., et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46 (2004) 65-72
45. Witjes J.A., Hendricksen K., Gofrit O., Risi O., and Nativ O. Intravesical hyperthermia and mitomycin-C for (BCG-refractory) carcinoma in situ of the urinary bladder. Eur Urol Suppl 6 (2007) 60 (abstract)
46. Colombo R., Brausi M., Da P.L., et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion. Eur Urol 39 (2001) 95-100
47. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170 (2003) 777-782
48. Di Stasi S.M., Giannantoni A., Giurioli A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7 (2006) 43-51
49. Waidelich R., Stepp H., Baumgartner R., Weninger E., Hofstetter A., and Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165 (2001) 1904-1907
50. Berger A.P., Steiner H., Stenzl A., Akkad T., Bartsch G., and Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 61 (2003) 338-341